ALC ALCON INC

NYSE alcon.com


$ 75.68 $ 0.49 (0.65 %)    

Tuesday, 21-Oct-2025 15:25:58 EDT
QQQ $ 612.01 $ 0.48 (0.08 %)
DIA $ 469.81 $ 2.69 (0.58 %)
SPY $ 672.06 $ 0.57 (0.08 %)
TLT $ 91.97 $ -0.01 (-0.02 %)
GLD $ 377.50 $ -9.14 (-2.36 %)
$ 75.46
$ 75.48
$ 75.65 x 12
$ 75.70 x 57
$ 75.25 - $ 75.96
$ 71.55 - $ 98.84
2,888,682
na
37.32B
$ 0.93
$ 36.66
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 keybanc-maintains-overweight-on-alcon-lowers-price-target-to-91

Keybanc analyst Brett Fishbin maintains Alcon (NYSE:ALC) with a Overweight and lowers the price target from $98 to $91.

Core News & Articles

Shareholders Have the Information They Need to Make an Informed VotePreliminary Net Sales Results for Third Quarter Underscore ...

Core News & Articles

Leading Proxy Advisory Firms ISS, Glass Lewis, and Egan-Jones, as well as Long-Term Shareholders Echo Broadwood's Concerns ...

 barclays-initiates-coverage-on-alcon-with-equal-weight-rating-announces-price-target-of-86

Barclays analyst Matt Miksic initiates coverage on Alcon (NYSE:ALC) with a Equal-Weight rating and announces Price Target of...

 btig-maintains-buy-on-alcon-lowers-price-target-to-91

BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:ALC) with a Buy and lowers the price target from $92 to $91.

Core News & Articles

Raises Concerns About Whether the Board Fulfilled Its Fiduciary Duty of Care in Doubling Down on Its Commitment to Proposed Tra...

Core News & Articles

Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or th...

Core News & Articles

STAAR Continues to Significantly Underestimate the Strength of the Business and Future Prospects and Misrepresent Its Performan...

Core News & Articles

Contends There Is No Business Justification for the Board's Decision to Sell the Company for $28 Per Share Now After Reject...

Core News & Articles

Broadwood Believes the Transaction Comes at the Wrong Time, After the Wrong Process, and at the Wrong PriceFor the Reasons Desc...

Core News & Articles

Broadwood Believes the Transaction Comes at the Wrong Time, After the Wrong Process, and at the Wrong PriceFor the Reasons Desc...

Core News & Articles

Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ...

 forecasting-the-future-10-analyst-projections-for-alcon

Analysts' ratings for Alcon (NYSE: ALC) over the last quarter vary from bullish to bearish, as provided by 10 analysts. In ...

 stifel-maintains-buy-on-alcon-lowers-price-target-to-85

Stifel analyst Thomas Stephan maintains Alcon (NYSE: ALC) with a Buy and lowers the price target from $90 to $85.

Core News & Articles

Proposed Merger Represents a Compelling 59% Premium to the 90-Day VWAP Prior to AnnouncementSTAAR's Business Risks and Chal...

Core News & Articles

Outlines Its Belief that the Proposed Transaction Is the Product of Bad Timing, a Flawed Process, and Significant Conflicts of ...

Core News & Articles

Reinforces STAAR Board's Determination that Alcon Merger Maximizes Stockholder Value and is Best Path Forward for STAAR Sto...

Core News & Articles

Issues Open Letter to Shareholders Outlining Its Belief that the Proposed Merger Materially Undervalues STAARContends that STAA...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION